ASTRO/SNO Joint Activity: Current Multidisciplinary Management of Molecularly Defined IDH Mutant Grade 2 - 3 Glioma - Who, What, When, Why and How?

The management of patients with grade 2 – 3 glioma has recently become even more complicated due to incorporation of molecular findings for pathologic diagnosis, changing criteria for who is considered high risk, and variability in the use and choice of chemotherapy with radiotherapy. This is an especially timely topic due to recent approval of the IDH inhibitor vorasidenib for IDH mutated low grade glioma. Additionally, there is little concrete direction in consensus guidelines for this patient population that tends to be younger and more heterogenous. This activity provides a multidisciplinary overview (radiotherapy, neuro-oncology and neurosurgery) of the modern approach to molecular defined grade 2 – 3 glioma and answer the questions of "who, what, when, why and how" for this disease. We discuss the molecular definitions for pathologic diagnosis based on the 2021 WHO criteria. A radiation oncologist discusses indications and planning considerations for RT, as well as expected radiation toxicities and how that may alter management decisions. A neuro-oncologist discusses the role of vorasidenib and indications and choice of PCV or temozolomide chemotherapy with RT. A neurosurgeon discusses the role of surgery and how that may differ based on molecular diagnosis and modern surgical techniques. Given the multidisciplinary nature of this disease, this is a joint activity with the Society of Neuro-Oncology (SNO) to provide critical perspectives to help inform radiation oncologists in their practice.

Topics:

  1. The Role of Surgery for IDH Mutant Gliomas: Evolving Indications in a Multidisciplinary Care Framework
    Pierpaolo Peruzzi, MD, PhD, FAANS
  2. Updates in Systemic Therapies for IDH Mutated Grade 2-3 Gliomas
    Jennie W. Taylor, MD, MPH
  3. Radiation Therapy for Grade 2-3 IDH-Mutant Gliomas: Evidence, Innovation and Evolving Practices
    Martin C. Tom, MD
  4. Q and A
    Roshan S. Prabhu, MD, MS - Moderator
    Full Panel

This activity is available from January 27, 2026, through 11:59 p.m. Eastern time on January 26, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, pathologists, radiation dosimetrists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the indications for radiotherapy for patients with grade 2 - 3 glioma and describe optimal planning techniques, dose considerations and potential acute and late toxicities.
  • Discuss the role of vorasidenib for IDH mutant grade 2-3 glioma and differentiate the options of PCV and temozolomide chemotherapy with RT.
  • Describe the role of surgery for grade 2 - 3 glioma and how extent of resection decisions may be influenced by molecular findings.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
01/27/2026
Course expires: 
01/26/2028
Cost:
$149.00
Rating: 
0

Moderator: 

  • Roshan S. Prabhu, MD, MS, is employed by Southeast Radiation Oncology Group. Dr. Prabhu has no relevant financial relationship with ineligible companies to disclose. 

Speakers:

  • Pierpaolo Peruzzi, MD, PhD, FAANS, is employed by Brigham and Women’s Hospital. Dr. Peruzzi has no relevant financial relationship with ineligible companies to disclose.
  • Jennie W. Taylor, MD, MPH, is employed by University of California, San Francisco. Dr. Taylor receives grant/research funding from Servier and Bristol Myers Squibb. 
  • Martin C. Tom, MD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Tom has no relevant financial relationship with ineligible companies to disclose.

Planners: 

  • Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until January 26, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.